- ECYT has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $8.9 million.
- ECYT has traded 379,573 shares today.
- ECYT is trading at 8.53 times the normal volume for the stock at this time of day.
- ECYT is trading at a new high 9.02% above yesterday's close.
'Strong on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as M&A events, material stock news, analyst upgrades, insider buying, buying from 'superinvestors,' or that hedge funds and momentum traders are piling into a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize. In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success. EXCLUSIVE OFFER: Get the inside scoop on opportunities in ECYT with the Ticky from Trade-Ideas. See the FREE profile for ECYT NOW at Trade-Ideas More details on ECYT:
Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. ECYT has a PE ratio of 21.9. Currently there are 4 analysts that rate Endocyte a buy, no analysts rate it a sell, and 3 rate it a hold.The average volume for Endocyte has been 1.1 million shares per day over the past 30 days. Endocyte has a market cap of $274.2 million and is part of the health care sector and drugs industry. The stock has a beta of 0.78 and a short float of 19.6% with 5.25 days to cover. Shares are down 35.7% year-to-date as of the close of trading on Monday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Endocyte as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, compelling growth in net income and reasonable valuation levels. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year. Highlights from the ratings report include:
- ECYT's very impressive revenue growth greatly exceeded the industry average of 4.6%. Since the same quarter one year prior, revenues leaped by 198.3%. Growth in the company's revenue appears to have helped boost the earnings per share.
- ENDOCYTE INC reported significant earnings per share improvement in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, ENDOCYTE INC reported poor results of -$0.50 versus -$0.47 in the prior year. This year, the market expects an improvement in earnings (-$0.10 versus -$0.50).
- The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. In comparison to the other companies in the Pharmaceuticals industry and the overall market, ENDOCYTE INC's return on equity is significantly below that of the industry average and is below that of the S&P 500.
- ECYT's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 54.97%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
- You can view the full Endocyte Ratings Report.